Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04301375
Title Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) (ELPIS)
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors David Garcia Cinca

Her2-receptor positive breast cancer


Paclitaxel + Pertuzumab + Trastuzumab

Ado-trastuzumab emtansine

Age Groups: senior | adult
Covered Countries ESP

No variant requirements are available.